On Friday, August 4, the Colorado Prescription Drug Affordability Board (PDAB) selected five drugs for affordability reviews: Enbrel, Genvoya, Cosentyx, Stelara, and Trikafta. PDAB staff plan to begin conducting affordability reviews for the first three and let stakeholders know how to engage. After completing the affordability review for each drug, the PDAB may or may not decide to impose an upper payment limit (UPL) for the drug in Colorado. CBSA will continue to actively advocate for the life sciences ecosystem and for patients as this important process moves forward.
Background
In 2021, the Colorado General Assembly passed SB21-175, which established the Prescription Drug Affordability Board (PDAB) “to evaluate and place upper price limits on the highest cost prescription drugs.” The five-member PDAB is charged with collecting prescription drug pricing information and determining which drugs should undergo an affordability review. If the PDAB determines that a drug…
Click here to view original post
